Translating @entity3986 microarray findings to novel biomarkers for @entity121 in XXXX .

@entity1 @entity82 @entity235 @entity3986 @entity1555 @entity2252 @entity1096 @entity299 @entity121
BACKGROUND: In @entity1555 ( @entity1555 ), abnormal cardiac function is typically preceded by a decade of @entity121 . Molecular reasons for differences in onset and progression of these muscle groups are unknown. @entity1 biomarkers are lacking. METHODS: We analyzed cardiac and skeletal muscle microarrays from normal and @entity3986 ( @entity3986 ) @entity235 (ages 6, 12, or 47+ mo) to gain insight into @entity121 and to identify putative @entity1555 biomarkers. These biomarkers were then measured using @entity1 @entity1555 blood samples. RESULTS: We identified @entity3986 candidate genes that might contribute to the disparity between @entity299 , focusing on @entity2252 ( @entity2252 ) and @entity1096 ( @entity1096 / @entity1096 , hereafter indicated as @entity1096 ). @entity2252 was elevated in cardiac muscle of younger @entity3986 but was unaltered in skeletal muscle, while @entity1096 was increased only in @entity3986 skeletal muscle. In @entity1 @entity1555 , circulating levels of @entity2252 were inversely correlated with ventricular function and @entity82 , while @entity1096 levels correlated with skeletal muscle function. CONCLUSION: These results highlight gene expression patterns that could account for differences in @entity299 in @entity3986 . Most notably, animal model-derived data were translated to @entity1555 and support use of @entity2252 and @entity1096 as biomarkers for cardiac and skeletal muscle involvement, respectively.
